Articles for Specialty Pharmaceuticals
June 6, 2014 | Cate Douglass
With specialty pharmaceuticals carrying extremely high-and rising-costs, nonadherence and discontinuation of therapy is becoming even more commonplace. The value-based insurance design (V-BID) model, so termed by A. Mark Fendrick, MD, Dean Smith, PhD, and Michael Chernew, MD, promotes personalized patient care by easing access to specialty medications while reducing the number of prescribed treatments of lesser value as a replacement.
June 19, 2013 | Dea Belazi, PharmD, MPH
August 2, 2012 | William N. Kelly, PharmD, FISPE; Jeoffrey Stross, MD; James Jorgenson, MS, RPH, FASHP; and Douglas E. Miller, PharmD
Strategies for controlling use of specialty pharmaceuticals should focus on situations where these agents are used inappropriately and on improvement of the complex billing process.
January 11, 2011 | James A. Jorgenson, RPh, MS
Over the last 20 years, specialty pharmacy has grown and changed significantly to better manage high-cost drugs with challenging reimbursement issues.
April 26, 2010 | Jan E. Berger, MD, MJ
Can value-based benefit design be used in specialty pharmacy to address costs and align incentives between patients and payers?